** Shares in DSM-Firmenich DSFIR jump around 14% to their highest level since May 2023 after the group reported annual profit beat helped by cost-saving measures and said it would carve out its animal nutrition and health business
** The company said its core adjusted net profit was 555 million euros ($595 million) in 2023, 14% above analysts’ expectations of 485 million, according to a company-compiled consensus
** Q4 EBITDA at 439 million euros is 1% better than consensus, according to J.P.Morgan, with the beat driven primarily by lower-than-expected corporate costs
** DSM-Firmenich’s stock reached the top of the Amsterdam blue-chip index (.AEX); if gains hold it will see its best day ever
DSM-Firmenich shares soar on animal nutrition biz separation plans — TradingView News